Genmab A+s

Cormorant Pharmaceuticals Ab

Medarex Inc.

Ole Baadsgaard

Paul Parren

Jørgen Petersen

Jan G J Van De Winkel

Janine Schuurman

Jan Van De Winkel

Arnout F Gerritsen

Marcus A Van Dijk

Jessica Teeling

Debra Hudson

Rene Hoet

Edward Norbert Van Den Brink

David Satijn

Denise Leah Williams

Bart De Goeij

Catharina Emanuele Gerarda Havenith

Simone De Haij

Thilo Riedl

Jorgen Petersen

Aran Frank Labrijn

Edward L Halk

Joyce Meesters

Tom Vink

Rob N De Jong

Sandra Verploegen

Willem Karel Bleeker

David P E Satijn

Steen Lisby

Vibeke Miller Breinholt

Eva Ehrnrooth

Mischa Houtkamp

Maroeska Oudshoorn

Jan Van Winkel

Edward N Brink

Haichun Huang

Yvo Graus

Martine Van Vugt

Martin John Glennie

Klaus Edvardsen

Michel De Weers

Judith Oprins

Sigrid Ruuls

Denis Alexander

Jørgen Peterson

Rene M A Hoet

Simone Haij

Rene MA Hoet

René Hoet

Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against HER2

Monoclonal antibodies against HER2 epitope

Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies against CD25

Human monoclonal antibodies against interleukin 8 (IL-8)

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Human antibodies against tissue factor and methods of use thereof

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.

Method of treating rash in patients undergoing anti-EGFR therapy

The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA.

Therapy with CD4 binding peptides and radiation

Growing community of inventors

Hellerup, Denmark

Ole Baadsgaard